Intrauterine Contraceptive Devices (IUCDs) Market Research Report - Global Forecast till 2025

Intrauterine Contraceptive Devices (IUCDs) Market Research Report - Global Forecast till 2025

ID: MRFR/HC/6977-HCR | November, 2019 | Region: Global | 85 pages | Half-Cooked Research Reports

Market Forecast


Intrauterine Contraceptive Devices (IUCDs) Market is expected to cross USD 2658.2 Million by 2025 at a CAGR of 10.5%.


Market Synopsis


The increasing awareness about contraceptive methods, increasing number of unintended pregnancies, and government support and initiatives for the prevention of unwanted abortions & pregnancies are set to drive the demand for intrauterine contraceptive devices (IUCDs) during the forecast period.


Birth controls have been used since ancient times, but the safe and effective methods from the 20th century are being implemented and available. Contraceptive methods are used to prevent unwanted pregnancy by preventing the natural ovulation cycle or altering the egg fertilization process. Intrauterine contraceptive devices are placed inside the uterus to avoid pregnancy. The device has a string that ensures the correct placement of the equipment inside the uterus and helps in the removal of the device. Intrauterine contraceptive devices can be used for 3,5 and 10 years. These devices are made up of plastic and metal and available in various shapes, such as coil, loop, triangle, and T-shaped.


Strategic mergers & acquisitions and new product launches are also projected to boost market growth with companies looking to strengthen their market positions, expand their product portfolios, and improves their brand images.  Many companies are working in collaboration with government and developing innovative and easy to use intrauterine contraceptive devices to strengthen its position in the global intrauterine contraceptive devices (IUCDs) market.


Market Influencer


The technological innovations are leading to effective contraception along with fewer side effects, which are strongly influencing the growth of the market and likely to provide favorable conditions for the growth of the market.   


Market Drivers



  • Increasing demand for easy to use, removable, and cost-effective contraceptives is responsible for the growth of the intrauterine contraceptive devices (IUCDs) market.  

  • The growth of the market is driven by a high number of unintended pregnancies, and favorable government initiatives for spreading awareness and encouraging the use of effective contraceptive methods are projected to have a synergistic effect on market growth. According to the MRFR analysis, more than 40% of pregnancies in Europe and around 35% in Asia are unplanned, leading to a high demand for intrauterine contraceptive devices (IUCDs).

  • fewer side-effects associated with the use of intrauterine contraceptive devices

  • The emergence of advanced intrauterine contraceptive devices (IUCDs) with high accuracy

  • The implementation of affordable care is also responsible for boosting the growth of the market during the forecast period.

  • Other benefits other than avoiding pregnancy, such as lighter periods and help in the menstrual cycle is likely to encourage the use of intrauterine contraceptive devices (IUCDs).


Market Restraints




  • Side effects associated with implantation of intrauterine contraceptive devices (IUCDs) such as intrauterine pregnancy and pelvic inflammatory disease (PID) is likely to hamper the growth of the Intrauterine Contraceptive Devices (IUCDs) market during the forecast period.




  • Additionally, Stringent regulatory guidelines and strict reimbursement policies are hindering the growth of the market.




Segmentation


By Type




  • Hormonal Intrauterine Device: These devices contain levonorgestrel, which helps to prevent pregnancy by changing the viscosity of cervical mucus to prevent sperm from reaching the egg. It can release levonorgestrel from 16 μg/day to 20 μg/day. These devices are used for 3, 5, or 7 years. Mirena, Skyla, and Liletta are some popular brands of Hormonal Intrauterine Devices. This segment is likely to register the highest CAGR during the forecast period.




  • Copper Intrauterine Device: Copper Intrauterine Devices are traditional devices which are in used since 1988 and considered as one of the most effective contraceptive devices. Paragard is one of the major brands in the copper intrauterine devices segment. Copper is toxic for sperms, and it kills sperms when it tries to enter the uterus. Copper intrauterine devices can be effectively used until ten years. Moreover, the use of copper intrauterine devices can cause heavier menstrual flow and cramps. This segment is expected to lead the market with maximum market share.




By End-User




  • Hospitals: Hospitals and health centers are expected to be the largest segment because hospitals and health centers are usually the primary points for diagnosis, treatment, and rehabilitation of individuals.




  • Gynecology Clinics: Consisting of long-term and accurate care for patients suffering from medical complications related to gynecology, this is a fast-growing market segment, especially in developed nations.




  • Community Health Care Centers: A small segment, these centers provide all primary medications and basic healthcare needs.




  • Others: Others segment includes small- and mid-scale healthcare centers, government organizations, and emergency centers.




By Region




  • Asia-Pacific: The Americas is the largest regional market for Intrauterine contraceptive devices (IUCDs), Asia-Pacific has the world’s largest population and a fast-developing healthcare sector. Additionally, the government in countries like India and China are encouraging youth population to use intrauterine contraceptive devices (IUCDs), and it is likely to drive the growth of the market. For instance, the Chinese government has implanted more than 350 million intrauterine contraceptive devices from 1980 to 2017 as a part of the birth control program.




  • Americas: The Americas is the second-largest regional market. An increasing number of unintended pregnancies, rising awareness about benefits of intrauterine contraceptive devices (IUCDs) along with the increasing healthcare expenditure in the region is also likely to drive the growth of the market during the assessment period.




  • Europe: Europe has some of the best healthcare services in the world. The demand for intrauterine contraceptive devices is high in this region due to the increasing number of healthcare centers in the region and government support along with the rising adoption of new technologies in the healthcare industry.




  • Middle East & Africa: Despite the developing healthcare infrastructure, intrauterine contraceptive devices (IUCDs) are used as a very effective birth control method, which is responsible for the rising demand for intrauterine contraceptive devices (IUCDs) in the region.




Key Players



  • Bayer AG

  • Eurogine, S.L.

  • The Cooper Companies, Inc.

  • Pfizer Inc.

  • HLL Lifecare Limited

  • OCON Healthcare

  • SMB Corporation

  • Egemen International

  • Meril Life Sciences Pvt. Ltd.

  • Mona Lisa N.V.

  • Prosan International B.V.

  • Pregna International Limited

  • Others

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY TYPE

6.1. Overview

Hormonal Intrauterine Device

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.2. Copper Intrauterine Device

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY END USER

7.1. Overview

7.2. Hospitals

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7.3. Gynecology Clinics

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7.4. Community Health Care Centers

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7.5. Others

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

8. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY REGION

8.1. Overview

8.2. Americas

8.2.1. North America

8.2.1.1. US

8.2.1.2. Canada

8.2.2. Latin America

8.3. Europe

8.3.1. Western Europe

8.3.1.1. Germany

8.3.1.2. France

8.3.1.3. Italy

8.3.1.4. Spain

8.3.1.5. UK

8.3.1.6. Rest of Western Europe

8.3.2. Eastern Europe

8.4. Asia-Pacific

8.4.1. Japan

8.4.2. China

8.4.3. India

8.4.4. Australia

8.4.5. South Korea

8.4.6. Rest of Asia-Pacific

8.5. Middle East & Africa

8.5.1. Middle East

8.5.2. Africa

9. COMPANY LANDSCAPE

9.1.1. Overview

9.1.2. Competitive Analysis

10. COMPANY PROFILES

10.1. Bayer AG

10.1.1. Company Overview

10.1.2. Product Type Overview

10.1.3. Financial Overview

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. EUROGINE, S.L.

10.2.1. Company Overview

10.2.2. Product Type Overview

10.2.3. Financial Overview

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. The Cooper Companies, Inc.

10.3.1. Company Overview

10.3.2. Product Type Overview

10.3.3. Financial Overview

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Pfizer

10.4.1. Company Overview

10.4.2. Product Type Overview

10.4.3. Financial Overview

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. HLL Lifecare Limited

10.5.1. Company Overview

10.5.2. Product Type Overview

10.5.3. Financial Overview

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. OCON Healthcare

10.6.1. Company Overview

10.6.2. Product Type Overview

10.6.3. Financial Overview

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. SMB Corporation

10.7.1. Company Overview

10.7.2. Product Type Overview

10.7.3. Financial Overview

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Egemen International

10.8.1. Company Overview

10.8.2. Product Type Overview

10.8.3. Financial Overview

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Meril Life Sciences Pvt. Ltd.

10.9.1. Company Overview

10.9.2. Product Type Overview

10.9.3. Financial Overview

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Mona Lisa N.V.

10.10.1. Company Overview

10.10.2. Product Type Overview

10.10.3. Financial Overview

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

10.11. Prosan International B.V.

10.11.1. Company Overview

10.11.2. Product Type Overview

10.11.3. Financial Overview

10.11.4. Key Developments

10.11.5. SWOT Analysis

10.11.6. Key Strategies

10.12. Pregna International Limited

10.12.1. Company Overview

10.12.2. Product Type Overview

10.12.3. Financial Overview

10.12.4. Key Developments

10.12.5. SWOT Analysis

10.12.6. Key Strategies

10.13. Others

11. APPENDIX

11.1. References

11.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET SYNOPSIS, 2019–2025

TABLE 2 GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET ESTIMATES & FORECAST, 2019–2025 (USD MILLION)

TABLE 3 GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 4 GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 5 GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY REGION, 2019–2025 (USD MILLION)

TABLE 6 NORTH AMERICA: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 7 NORTH AMERICA: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 8 US: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 9 US: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 10 CANADA: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 11 CANADA: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 12 LATIN AMERICA: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 13 LATIN AMERICA: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 14 EUROPE: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 15 EUROPE: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 16 WESTERN EUROPE: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 17 WESTERN EUROPE: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 18 EASTERN EUROPE: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 19 EASTERN EUROPE: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 20 ASIA-PACIFIC: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 21 ASIA-PACIFIC: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY TYPE, 2019–2025 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET, BY END USER, 2019–2025 (USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET

FIGURE 4 GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET SHARE, BY TYPE, 2018 (%)

FIGURE 5 GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET SHARE, BY END USER, 2018 (%)

FIGURE 6 GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET SHARE, BY REGION, 2018 (%)

FIGURE 7 AMERICAS: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET SHARE BY REGION, 2018 (%)

FIGURE 7 NORTH AMERICA: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 8 EUROPE: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET SHARE, BY REGION, 2018 (%)

FIGURE 9 WESTERN EUROPE: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 10 ASIA-PACIFIC: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 11 MIDDLE EAST & AFRICA: INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 12 GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES (IUCDS) MARKET: COMPANY SHARE ANALYSIS, 2018 (%)

FIGURE 13 BAYER AG: KEY FINANCIALS

FIGURE 14 BAYER AG: SEGMENTAL REVENUE

FIGURE 15 BAYER AG: REGIONAL REVENUE

FIGURE 16 EUROGINE, S.L.: KEY FINANCIALS

FIGURE 17 EUROGINE, S.L.: SEGMENTAL REVENUE

FIGURE 18 EUROGINE, S.L.: REGIONAL REVENUE

FIGURE 19 THE COOPER COMPANIES, INC.: KEY FINANCIALS

FIGURE 20 THE COOPER COMPANIES, INC.: SEGMENTAL REVENUE

FIGURE 21 THE COOPER COMPANIES, INC.: REGIONAL REVENUE

FIGURE 22 PFIZER: KEY FINANCIALS

FIGURE 23 PFIZER: SEGMENTAL REVENUE

FIGURE 24 PFIZER: REGIONAL REVENUE

FIGURE 25 HLL LIFECARE LIMITED: KEY FINANCIALS

FIGURE 26 HLL LIFECARE LIMITED: SEGMENTAL REVENUE

FIGURE 27 HLL LIFECARE LIMITED: REGIONAL REVENUE

FIGURE 28 OCON HEALTHCARE: KEY FINANCIALS

FIGURE 29 OCON HEALTHCARE: SEGMENTAL REVENUE

FIGURE 30 OCON HEALTHCARE: REGIONAL REVENUE

FIGURE 31 SMB CORPORATION: KEY FINANCIALS

FIGURE 32 SMB CORPORATION: SEGMENTAL REVENUE

FIGURE 33 SMB CORPORATION: REGIONAL REVENUE

FIGURE 34 EGEMEN INTERNATIONAL: KEY FINANCIALS

FIGURE 35 EGEMEN INTERNATIONAL: SEGMENTAL REVENUE

FIGURE 36 EGEMEN INTERNATIONAL: REGIONAL REVENUE

FIGURE 37 MERIL LIFE SCIENCES PVT. LTD.: KEY FINANCIALS

FIGURE 38 MERIL LIFE SCIENCES PVT. LTD.: SEGMENTAL REVENUE

FIGURE 39 MERIL LIFE SCIENCES PVT. LTD.: REGIONAL REVENUE

FIGURE 40 MONA LISA N.V.: KEY FINANCIALS

FIGURE 41 MONA LISA N.V.: SEGMENTAL REVENUE

FIGURE 42 MONA LISA N.V.: REGIONAL REVENUE

FIGURE 43 PROSAN INTERNATIONAL B.V.: KEY FINANCIALS

FIGURE 44 PROSAN INTERNATIONAL B.V.: SEGMENTAL REVENUE

FIGURE 45 PROSAN INTERNATIONAL B.V.: REGIONAL REVENUE

FIGURE 46 PREGNA INTERNATIONAL LIMITED: KEY FINANCIALS

FIGURE 47 PREGNA INTERNATIONAL LIMITED: SEGMENTAL REVENUE

FIGURE 48 PREGNA INTERNATIONAL LIMITED: REGIONAL REVENUE



This table of content is tentative and subject to change as the research progresses.

Please note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.